Consistent in vitro scratch assay device
exploratoryresearch program · high
Enable more consistent and reproducible in vitro scratch assays for wound-healing research, including use in 96-well plates.
Flexible scratch device comprising a single wounding tool, a guide, and an imaging template to standardize scratch creation and longitudinal imaging regions of interest.
2023 BMC Biotechnology publication reported development and validation of the scratch assay device.
The device produced a more consistent scratch profile than conventional pipette-tip scratching and helped operators image the same region of interest at different time points.
Delayed scratch closure chronic wound assay
exploratoryresearch program · high
Create an in vitro wound-healing assay that better mimics delayed closure and inflammatory features of chronic wounds for screening drugs or biological treatments.
Defined scratch assay in human keratinocyte HaCaT and human dermal fibroblast cells, stimulated with pro-inflammatory factors including interferon, PMA, and lipopolysaccharide to delay scratch closure; responsiveness tested using proprietary human Wharton's jelly MSC secretome.
2024 publications described development and functional testing of the delayed scratch closure assay, including a Methods in Molecular Biology protocol publication.
The assay produced delayed closure and increased inflammation-like features; chronically open HaCaT scratches showed closure after exposure to MSC secretome product.
Human Wharton's jelly MSC secretome wound-healing program
preclinicaldrug program · high
Develop a secretome-based wound-healing product that accelerates closure and tissue repair, including applications relevant to acute and chronic wound models.
Secretome derived from prolonged high-density industrial-scale human Wharton's jelly stem cell culture; tested in cell proliferation assays, scratch closure assays, 3D de-epidermised dermis human skin equivalent wounds, and an in vivo rat acute wound model.
2025 publication reported wound-healing effects of industrial-scale Wharton's jelly stem cell secretome in in vitro, ex vivo-like skin equivalent, and rat wound models.
Secretome treatment dose-dependently increased cell proliferation, promoted scratch closure, accelerated wound closure in 3D human skin equivalent wounds, and enhanced rat wound healing via re-epithelialisation, vascularisation, and granulation maturation.
Stem cell secretome-based regenerative biologics platform
undisclosedplatform · medium
Develop secretome-based regenerative biologics for therapeutics, cosmeceuticals, veterinary health, and longevity-oriented applications.
Stem cell secretome technologies derived from stem cell sources, including human Wharton's jelly mesenchymal stem cell secretome referenced in publications.
Platform described on company site with validation through institutional collaborations, peer-reviewed publication, and internal platform data.
Company materials state the platform is validated through collaborations, publication, and internal data; supplied publication evidence shows wound-healing activity of MSC secretome in vitro and in vivo.
